Almirall and simcere
WebSep 29, 2024 · Nanjing China and Barcelona Spain, September 29, 2024, Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical … WebSep 28, 2024 · Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an ...
Almirall and simcere
Did you know?
WebOct 6, 2024 · Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune … WebOct 4, 2024 · Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, …
WebSep 29, 2024 · Get 7 Days Free Sign In Sign In Topics WebSep 29, 2024 · NANJING, China, Sept. 29, 2024 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere's IL-2 …
WebOct 12, 2024 · Simcere Pharmaceutical Group(2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical … WebSep 29, 2024 · September 29, 2024 at 02:02 AM EDT. Simcere will receive a $15 million upfront payment and up to US$492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon future …
WebSimcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A, a global biopharmaceutical company focused on skin health; have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.
WebSep 29, 2024 · Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group （2096.HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune … l2tp nat windows 10WebWe are thrilled to announce that, Simcere has entered into an exclusive licensing agreement with #Almirall for Simcere's IL-2 mutant fusion protein (IL-2 mu Fc) autoimmune drug candidate, SIM0278 ... l2tp or ipsecWebSep 29, 2024 · Simcere and Almirall announced Thursday that the two companies had reached a deal for Simcere’s IL-2 mutant fusion protein drug candidate, called SIM0278. According to a statement, Almirall... l2tp over ipsec nat穿越l2tp network managerWebSep 29, 2024 · Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D … prohealth clinical researchWebSep 29, 2024 · NANJING, China, Sept. 28, 2024 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall … l2tp layer two tunnelling protocolWebAlmirall and Simcere enter into a licensing agreement for IL-2-mu-Fc • Simcere will receive a $15 million upfront payment and up to US$492 million in development and commercial … l2tp overhead